IFN-α6 Activators
IFN-α6 activators encompass a diverse group of chemicals that indirectly enhance the activity or production of Interferon alpha-6 (IFN-α6). This group primarily includes small molecules and synthetic analogs that target various components of the immune response and signaling pathways. For instance, compounds like Poly(I:C), Imiquimod, and Resiquimod function as agonists for toll-like receptors (TLRs), particularly TLR3, TLR7, and TLR8. Activation of these receptors leads to the downstream signaling cascades that result in the production of type I interferons, including IFN-α6. This mechanism is crucial for the innate immune response against viral infections and other pathogenic challenges.
On the other hand, several members of this group, such as JAK inhibitors (Ruxolitinib, Tofacitinib) and PI3K pathway inhibitors (like PIK-III), demonstrate their role in modulating IFN-α6 activity indirectly through the regulation of key signaling pathways. JAK-STAT signaling is a critical pathway for the action of interferons, including IFN-α6. Inhibitors targeting this pathway may paradoxically lead to feedback mechanisms that enhance IFN-α6 expression or activity. Similarly, PI3K pathway inhibitors can affect various cellular processes, including those related to interferon signaling and production.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Polyinosinic acid - polycytidylic acid sodium salt, double-stranded | 42424-50-0 | sc-204854 sc-204854A | 10 mg 100 mg | $139.00 $663.00 | 2 | |
A synthetic analog of double-stranded RNA, known to induce IFN-α production, including IFN-α6, by stimulating toll-like receptor 3 (TLR3). | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $67.00 $284.00 | 6 | |
An immune response modifier that activates toll-like receptor 7 (TLR7), leading to increased production of IFN-α. | ||||||
R-848 | 144875-48-9 | sc-203231 sc-203231A sc-203231B sc-203231C | 5 mg 25 mg 100 mg 500 mg | $102.00 $306.00 $510.00 $1559.00 | 12 | |
Similar to Imiquimod, this chemical activates TLR7 and TLR8, promoting IFN-α production. | ||||||
Gardiquimod | 1020412-43-4 | sc-221663 sc-221663A sc-221663B sc-221663C sc-221663D sc-221663E sc-221663F | 25 mg 50 mg 100 mg 250 mg 5 g 10 g 25 g | $157.00 $282.00 $516.00 $1177.00 $20138.00 $32779.00 $70753.00 | 1 | |
A TLR7 agonist that stimulates the production of type I interferons including IFN-α. | ||||||
JAK Inhibitor I | 457081-03-7 | sc-204021 sc-204021A | 500 µg 1 mg | $156.00 $339.00 | 59 | |
Although primarily an inhibitor, it can indirectly upregulate IFN-α activity by modulating JAK-STAT signaling. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
A JAK1 and JAK2 inhibitor, known to affect IFN-α signaling indirectly. | ||||||
PIK-III | 1383716-40-2 | sc-507530 | 5 mg | $170.00 | ||
Specifically inhibits PIKfyve, influencing vesicular trafficking and potentially affecting IFN-α signaling. | ||||||
BX 795 | 702675-74-9 | sc-281689 sc-281689A sc-281689C sc-281689B sc-281689D sc-281689E | 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg | $219.00 $273.00 $331.00 $495.00 $882.00 $1489.00 | 5 | |
Targets TBK1/IKKε, affecting signaling pathways involved in IFN-α production. | ||||||
Amlexanox | 68302-57-8 | sc-217630 | 10 mg | $160.00 | 2 | |
An inhibitor of TBK1 and IKKε, potentially influencing IFN-α6 signaling pathways. | ||||||